Article

Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands.

Emma Children's Hospital/Academic Medical Centre, Amsterdam, The Netherlands.
Journal of Pediatric Gastroenterology and Nutrition (impact factor: 2.3). 07/2004; 39(1):46-52. pp.46-52
Source: PubMed

ABSTRACT The purpose of this study was to describe the clinical experience with the anti-tumor necrosis factor chimeric monoclonal antibody, infliximab, in pediatric patients with Crohn disease in The Netherlands.
Descriptive.
Clinical response and adverse effects of infliximab were recorded for pediatric patients with Crohn disease treated from October 1992 to January 2003.
Thirty patients (aged 7-18 years) with refractory Crohn disease (with or without severe fistulas) were treated with infliximab. Patients were treated with up to 30 infusions. Mean follow-up was 25.3 months. A total of 212 infusions were administered. Thirteen patients had refractory Crohn disease without fistulas. Six patients showed good long-term response to infliximab treatment (defined as clinical index < or =10 points). Sixteen patients had refractory Crohn disease with draining fistulas. Nine showed good long-term response (closure or nonproductiveness of fistulas). One patient with metastatic Crohn disease in the skin had a good long-term response. Six patients developed an allergic reaction during infusion. In one patient, the allergic reaction occurred after an infliximab-free interval of 9 years. One patient died of sepsis.
Infliximab was an effective therapy in 53% of patients with refractory pediatric Crohn disease, with or without fistulas. Approximately half of the patients become unresponsive to infliximab therapy. Randomized controlled studies are mandatory to assess long-term efficacy and safety to define the optimal therapeutic strategy of infliximab therapy in children with Crohn disease.

0 0
 · 
0 Bookmarks
 · 
34 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Full-text

View
0 Downloads
Available from

Keywords

212 infusions
 
30 infusions
 
allergic reaction
 
anti-tumor necrosis factor chimeric monoclonal antibody
 
clinical experience
 
clinical index
 
Clinical response
 
Crohn disease
 
draining fistulas
 
good long-term response
 
infliximab therapy
 
infliximab treatment
 
infliximab-free interval
 
long-term efficacy
 
Mean follow-up
 
metastatic Crohn disease
 
pediatric patients
 
refractory Crohn disease
 
refractory pediatric Crohn disease
 
severe fistulas